Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
Published 2015 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models
Authors
Keywords
Cancer treatment, Pediatrics, DNA damage, Apoptosis, Gene amplification, Medulloblastoma, Neuroblastoma, Glioma
Journal
PLoS One
Volume 10, Issue 11, Pages e0142612
Publisher
Public Library of Science (PLoS)
Online
2015-11-25
DOI
10.1371/journal.pone.0142612
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A novel germline mutation of PDGFR-βmight be associated with clinical response of colorectal cancer to regorafenib
- (2014) M. Rechsteiner et al. ANNALS OF ONCOLOGY
- PDGF receptor signaling networks in normal and cancer cells
- (2014) Jean-Baptiste Demoulin et al. CYTOKINE & GROWTH FACTOR REVIEWS
- Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
- (2013) B. Schultheis et al. ANNALS OF ONCOLOGY
- Antitumor efficacy of the heparanase inhibitor SST0001 alone and in combination with antiangiogenic agents in the treatment of human pediatric sarcoma models
- (2013) G. Cassinelli et al. BIOCHEMICAL PHARMACOLOGY
- PDGFRAAmplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma
- (2013) Joanna J. Phillips et al. BRAIN PATHOLOGY
- Reversibility of regorafenib effects in hepatocellular carcinoma cells
- (2013) Rosalba D’Alessandro et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Novel Oncogenic PDGFRA Mutations in Pediatric High-Grade Gliomas
- (2013) B. S. Paugh et al. CANCER RESEARCH
- Targeting the PDGF signaling pathway in tumor treatment
- (2013) Carl-Henrik Heldin Cell Communication and Signaling
- Regorafenib Inhibits Growth, Angiogenesis, and Metastasis in a Highly Aggressive, Orthotopic Colon Cancer Model
- (2013) L. Abou-Elkacem et al. MOLECULAR CANCER THERAPEUTICS
- Phase II study of irinotecan in combination with temozolomide (TEMIRI) in children with recurrent or refractory medulloblastoma: a joint ITCC and SIOPE brain tumor study
- (2013) J. Grill et al. NEURO-ONCOLOGY
- Fibroblast Growth Factor Receptors as Novel Therapeutic Targets in SNF5-Deleted Malignant Rhabdoid Tumors
- (2013) Simon Wöhrle et al. PLoS One
- A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors
- (2012) K. Mross et al. CLINICAL CANCER RESEARCH
- FGFR4 Blockade Exerts Distinct Antitumorigenic Effects in Human Embryonal versus Alveolar Rhabdomyosarcoma
- (2012) L. E. S. Crose et al. CLINICAL CANCER RESEARCH
- Efficacy and Safety of Regorafenib in Patients With Metastatic and/or Unresectable GI Stromal Tumor After Failure of Imatinib and Sunitinib: A Multicenter Phase II Trial
- (2012) Suzanne George et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) George D Demetri et al. LANCET
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
- (2012) Axel Grothey et al. LANCET
- Vascular endothelial growth factor serum levels in children with newly diagnosed rhabdomyosarcoma
- (2012) Amalia Schiavetti et al. PEDIATRIC BLOOD & CANCER
- Mesenchymal Transition and PDGFRA Amplification/Mutation Are Key Distinct Oncogenic Events in Pediatric Diffuse Intrinsic Pontine Gliomas
- (2012) Stephanie Puget et al. PLoS One
- An in-vitro evaluation of the polo-like kinase inhibitor GW843682X against paediatric malignancies
- (2011) Kristina Spaniol et al. ANTI-CANCER DRUGS
- The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts
- (2010) Jochen Rössler et al. INTERNATIONAL JOURNAL OF CANCER
- Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
- (2010) Scott M. Wilhelm et al. INTERNATIONAL JOURNAL OF CANCER
- Lack of Efficacy of Bevacizumab Plus Irinotecan in Children With Recurrent Malignant Glioma and Diffuse Brainstem Glioma: A Pediatric Brain Tumor Consortium Study
- (2010) Sridharan Gururangan et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease
- (2010) Barbara S. Paugh et al. JOURNAL OF CLINICAL ONCOLOGY
- Bevacizumab in recurrent high-grade pediatric gliomas
- (2010) A. Narayana et al. NEURO-ONCOLOGY
- High Levels of Circulating VEGFR2+ Bone Marrow-Derived Progenitor Cells Correlate with Metastatic Disease in Patients with Pediatric Solid Malignancies
- (2009) M. Taylor et al. CLINICAL CANCER RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started